These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23036676)

  • 1. Changes in serum prostate-specific antigen levels.
    Keller DL
    Mayo Clin Proc; 2012 Oct; 87(10):1033; author reply 1033. PubMed ID: 23036676
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA
    J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prostate-specific antigen in cancer and benign prostatic hyperplasia].
    Kushlinskiĭ NE; Liubimova NV; Gorilovskiĭ LM
    Biull Eksp Biol Med; 1997 Sep; 124(9):327-30. PubMed ID: 9445619
    [No Abstract]   [Full Text] [Related]  

  • 4. A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia.
    Jung K; Brux B; Knäbich A; Lein M; Sinha P; Schnorr D; Loening SA
    Clin Chem; 1999 Mar; 45(3):422-4. PubMed ID: 10053050
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
    Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
    Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free prostate-specific antigen in serum is becoming more complex.
    Mikolajczyk SD; Marks LS; Partin AW; Rittenhouse HG
    Urology; 2002 Jun; 59(6):797-802. PubMed ID: 12031356
    [No Abstract]   [Full Text] [Related]  

  • 7. Workgroup #3: Monitoring effects of treatment for cancer and for benign prostatic hyperplasia.
    Jones GW; Smith RA; Batjer JD; Bostwick DG; Corn BW; Guess HA; Hudson MA; Kabalin J; Soloway MS
    Cancer; 1993 Apr; 71(8):2681-3. PubMed ID: 7680953
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    J Urol; 1997 Apr; 157(4):1371. PubMed ID: 9120953
    [No Abstract]   [Full Text] [Related]  

  • 9. [Measurement of complexed prostatic specific antigen. A new challenge in PSA era].
    Morote Robles J
    Med Clin (Barc); 2004 Feb; 122(7):256-8. PubMed ID: 15012874
    [No Abstract]   [Full Text] [Related]  

  • 10. The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume.
    Stephan C; Jung K; Lein M; Schnorr D; Loening SA
    Int J Cancer; 1996 Jul; 67(3):461-2. PubMed ID: 8707426
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic specific antigen (PSA).
    Alberti C
    Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate].
    Morote J; Encabo G; Andreu J; de Torres I
    Med Clin (Barc); 1996 Dec; 107(20):795-6. PubMed ID: 9019610
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate-specific antigen and other prostate cancer markers.
    Stenman U; Finne P; Zhang W; Leinonen J
    Urology; 2000 Dec; 56(6):893-8. PubMed ID: 11113726
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of prostatic massage on serum levels of prostatic acid phosphatase and specific antigen].
    Sahin A; Ozen H; Balbay D; Bircan K; Koray Z; Karaagaoglu E; Remzi D
    Bull Cancer; 1992; 79(11):1097-100. PubMed ID: 1284587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardization of immunoassays for prostate specific antigen. A different view based on experimental observations.
    Stamey TA; Prestigiacomo AF; Chen Z
    Cancer; 1994 Sep; 74(6):1662-6. PubMed ID: 7521782
    [No Abstract]   [Full Text] [Related]  

  • 17. Significance of examination of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hyperplasia and prostate cancer.
    Romics I; Frang D; Bodrogi I
    Int Urol Nephrol; 1997; 29(4):449-55. PubMed ID: 9406003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term prostate-specific antigen trends following subcapsular prostatectomy.
    Klausner AP; Anderson BB; Espy PG; Despradel VM; Grob BM
    Can J Urol; 2010 Dec; 17(6):5442-6. PubMed ID: 21172107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostate specific antigen and NF-kB in prostatic disease: relation with malignancy].
    Cansino JR; Vera R; Rodríguez de Bethencourt F; Bouraoui Y; Rodríguez G; Prieto A; de la Peña J; Paniagua R; Royuela M
    Actas Urol Esp; 2011 Jan; 35(1):16-21. PubMed ID: 21256390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.